Advanced Filters
noise
Found 1,621 clinical trials
A Alejandra D Portillo Romero, MD

Randomized Trial Comparing Two Sirolimus-Eluting Stents in Diabetes Mellitus

Randomized, controlled, blind, single-center and non-inferiority clinical trial to compare the target lesion failure (TLF) at 12 months in patients with diabetes mellitus who underwent percutaneous coronary intervention with an Orsiro stent vs. Abluminus stent.

18 years of age All Phase N/A
I Issa Sabi, MD, MMed, PhD

Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus

Diabetes mellitus (DM) increases susceptibility to Tuberculosis (TB) and worsens TB patient outcomes. The number of patients with combined TB and DM now outnumbers that of combined TB and HIV and it has been estimated that 15-30% of TB disease may be attributable to diabetes globally. This may be expected …

18 years of age All Phase 3
F FOUSSARD NINON, Dr

New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.

Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence …

18 - 99 years of age All Phase N/A
E Emmanuel COSSON, Pr

Myo-inositol for Reduction of Insulin Therapy in Gestational Diabetes Mellitus

Gestational diabetes mellitus (GDM) is defined as hyperglycemia first-diagnosed during pregnancy. Glycemic control reduces GDM-related complications. With the new diagnostic criteria of GDM, up to 25% of pregnant women have GDM, whereas it was previously 6-10% in France. Therefore caring for women with GDM is very time-consuming. Therapeutic strategy includes …

18 - 45 years of age All Phase N/A
I Irit Ayalon Dangur, Dr

Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients

Hyperglycemia is a common condition among hospitalized patients. The occurrence of severe hyperglycemia is associated with increased morbidity and mortality in several populations. Several trials assessed the benefits of aggressive versus conventional glucose control. These studies evaluated different patient populations, glucose targets and treatment protocols and as a result reported …

18 - 120 years of age All Phase N/A

Evaluation Conducted to Capture Patients With Diabetic Retinopathy in General Practitioners, Using SW as Medical Device

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using AI medical device

40 years of age All Phase N/A
A Anson-Wisniewska

Surveillance of Pancreatic Health After Diabetes Diagnosis

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: attend 3 study visits over 12 months time provide a blood sample at each …

50 - 84 years of age All Phase N/A
C Catherine CAMPINOS

Assessment of HGI (Hemoglobin Glycation Index) Variability Over Time in Patients Living with Diabetes Using Continuous Glucose Monitoring ( GAP OUEST )

The goal of this clinical trial is to learn about the variability of HGI (Hemoglobin Glycation Index) over time in patients living with diabetes using a continuous glucose monitoring.

18 years of age All Phase N/A
S Sybil CHARRIERE

Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes

The main objective of the study is to assess the contribution of whole genome sequencing (WGS) coupled with a multidisciplinary conciliation meeting (MCM) on diagnosis of atypical forms of diabetes compared to an in-silico analysis of a panel of validated genes (ISApanel), corresponding to current practice, in a randomized trial. …

18 years of age All Phase N/A
J Jun Jiang, MD

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

The purpose of this study is to determine the superiority of the effectiveness of Henagliflozin 10 milligram (mg) daily versus blank control in participants with type II diabetes (T2DM) and symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS).

18 years of age All Phase N/A

Simplify language using AI